Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma

References

• Orth M, Lauber K, Niyazi M, Friedl AA, Li M, Maihofer C, Schuttrumpf L, Ernst A, Niemoller OM, Belka C. Current concepts in clinical radiation oncology. Radiat Environ Biophysr. 2014;53:1–29. PMID:24141602. doi:10.1007/s00411-013-0497-2.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Formenti S, Demaria S. Toward precision radiotherapy for use with immune checkpoint blockers. Clin Cancer Resr. 2018;24:259–265. PMID:28751442. doi:10.1158/1078-0432.CCR-16-0037.
   PubMed Web of Science ®Google Scholar
• Formenti S. Optimizing dose per fraction: A new chapter in the story of the abscopal effect? Int J Radiat Oncol Biol Physr. 2017;99:677–679. PMID:29280462. doi:10.1016/j.ijrobp.2017.07.028.
   PubMed Web of Science ®Google Scholar
• Valenzuela MT, Nunez MI, Guerrero MR, Villalobos M, Ruiz de Almodovar JM. Capillary electrophoresis of DNA damage after irradiation: apoptosis and necrosis. J Chromatogr Ar. 2000;871:321–330, PMID:10735312. doi:10.1016/S0021-9673(99)01245-5.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancerr. 2012;12:860–875. PMID:23151605. doi:10.1038/nrc3380.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira J, Delaloge S, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Revr. 2007;220:47–59. PMID: 17979839. doi:10.1111/j.1600-065X.2007.00573.x.
   PubMed Web of Science ®Google Scholar
• Frey B, Ruckert M, Deloch L, Ruhle PF, Derer A, Fietkau R, Gaipl US. Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. Immunol Revr. 2017;280:231–248. PMID:29027224. doi:10.1111/imr.12572.
   PubMed Web of Science ®Google Scholar
• Medler T, Cotechini T, Coussens L. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer. 2015;1:66–75. PMID: 26457331. doi:10.1016/j.trecan.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncolr. 2015;51:221–228. PMID: 25500094. doi:10.1016/j.oraloncology.2014.11.014.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Medr. 2016;8:328rv324. PMID:26936508. doi:10.1126/scitranslmed.aad7118.
   Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunolr. 2008;8:467–477. PMID:18500231. doi:10.1038/nri2326.
   PubMed Web of Science ®Google Scholar
• Taube J, Anders R, Young G, Xu H, Sharma R, McMiller T, Chen S, Klein A, Pardoll D, Topalian S, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Medr. 2012;4:127ra137. PMID: 22461641. doi:10.1126/scitranslmed.3003689
   Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Medr. 2013;369:122–133. PMID:23724867. doi:10.1056/NEJMoa1302369.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Naturer. 2014;515:568–571. PMID:25428505. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Medr. 2012;366:2443–2454. PMID:22658127. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Medr. 2010;207:2187–2194. PMID:20819927. doi:10.1084/jem.20100643.
   PubMed Web of Science ®Google Scholar
• Ribas A. 2012. Tumor immunotherapy directed at PD-1.. N Engl J Medr. 366:2517–2519. doi:10.1056/NEJMe1205943.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Resr. 2013;19:462–468. PMID:23169436. doi:10.1158/1078-0432.CCR-12-2625.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Naturer. 2014;515:558–562. PMID:25428503,doi: 10.1038/nature13904. . doi:10.1038/nature13904.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp K, Baas P, Crinò L, Eberhardt W, Poddubskaya E, Antonia S, Pluzanski A, Vokes E, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Medr. 2015;373:123–135. PMID: 26028407. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Medr. 2015;373:1803–1813. PMID:26406148. doi:10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Siva S, MacManus MP, Martin RF, Oa M. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lettr. 2015;356:82–90. PMID:24125863. doi:10.1016/j.canlet.2013.09.018.
   PubMed Web of Science ®Google Scholar
• Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Revr. 2017;280:249–279. PMID: 29027221. doi:10.1111/imr.12573.
   PubMed Web of Science ®Google Scholar
• Mole R. Whole body irradiation; radiobiology or medicine? Br J Radiolr. 1953;26:.234–241. doi:10.1259/0007-1285-26-305-234.
   PubMed Web of Science ®Google Scholar
• Derer A, Spiljar M, Bäumler M, Hecht M, Fietkau R, Frey B, Gaipl U. Chemoradiation Increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunolr. 2016;7:610. PMID: 28066420. doi:10.3389/fimmu.2016.00610.
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Clump D, Srivastava R, Sun L, Zeng D, Diaz-Perez J, Anderson C, Edwards W, Ferris R. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunologyr. 2017;6:7. PMID: 28811971. doi:10.1080/2162402X.2017.1329071.
   Web of Science ®Google Scholar
• Weichselbaum R, Liang H, Deng L, Fu Y. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncolr. 2017;14:365–379. PMID: 28094262. doi:10.1038/nrclinonc.2016.211.
   PubMed Web of Science ®Google Scholar
• Ngwa W, Irabor O, Schoenfeld J, Hesser J, Demaria S, Formenti S. Using immunotherapy to boost the abscopal effect. Nat Rev Cancerr. 2018;18:313–322. PMID: 29449659. doi:10.1038/nrc.2018.6.
   PubMed Web of Science ®Google Scholar
• Wang M, Wang H, Tang Y, Kang D, Gao Y, Ke M, Dou J, Xi T, Zhou C. Effective inhibition of a Strongylocentrotus nudus eggs polysaccharide against hepatocellular carcinoma is mediated via immunoregulation in vivo. Immunol Lettr. 2011;141:74–82. PMID: 21893096. doi:10.1016/j.imlet.2011.08.001.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Resr. 2013;73:3591–3603. PMID:23633484. doi:10.1158/0008-5472.CAN-12-4100.
   PubMed Web of Science ®Google Scholar
• Dovedi S, Adlard A, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle E, Stratford I, Poon E, Morrow M, Stewart R, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Resr. 2014;74:5458–5468. PMID: 25274032. doi:10.1158/0008-5472.CAN-14-1258.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Investr. 2002;109:651–659. PMID:11877473. doi:10.1172/JCI14184.
   PubMed Web of Science ®Google Scholar
• Xu HS, Wu YW, Xu SF, Sun HX, Chen FY, Yao L. Antitumor and immunomodulatory activity of polysaccharides from the roots of Actinidia eriantha. J Ethnopharmacolr. 2009;125:310–317. PMID:19559777. doi:10.1016/j.jep.2009.06.015.
   PubMed Web of Science ®Google Scholar